{"filings":[{"id":1582996,"accession_number":"0001104659-26-082719","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2026-07-10T21:13:07+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cellectar shareholders approve warrant exercise for up to 39.6M shares, increase share reserve by 2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Andrew Gu and Douglas J. Swirsky elected to three-year terms.","Shareholders approved 2,000,000 share increase under 2021 Stock Incentive Plan.","Shareholders approved exercise of warrants for up to 39,618,078 shares of common stock.","Deloitte & Touche ratified as independent auditor for fiscal year 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":499445,"accession_number":"0001104659-26-063202","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2026-05-18T20:15:33+00:00","items":["5.02"],"status":"ready","headline":"Cellectar director Loren not standing for reelection; Nantahala analyst Gu appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Stefan Loren will not stand for reelection at 2026 annual meeting; no disagreement with the company.","Loren enters consulting agreement: $15,000/quarter for one year, plus 15,000 stock option grant.","Andrew Gu appointed as Class III director on May 18, 2026, selected by Nantahala Capital Management.","Gu is an analyst at Nantahala, focuses on biotech; he joins the Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77601,"accession_number":"0001104659-26-060693","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2026-05-14T11:20:27+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar reports Q1 net loss $5.7M; positive iopofosine data, up to $140M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $5.7M ($1.33/share) vs $6.6M ($4.30/share) YoY; cash $8.3M at March 31.","Positive 12-month follow-up from CLOVER WaM: 61.8% MRR, 83.6% ORR, median PFS 13.5 months in r/r WM.","Completed $35M upfront + up to $105M milestone financing led by Nantahala Capital; Andrew Gu to join board.","Initiated Phase 1b trial of CLR 125 in triple negative breast cancer; first patient dosed. Dosimetry data expected mid-2026.","Selected for ASCO 2026 presentation of CLOVER-WaM subgroup data on iopofosine post-BTKi therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91886,"accession_number":"0001104659-26-057460","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$35M; issued 1.6M registered shares, 2.1M unregistered, and warrants for 9.5M+13.2M shares.","Phase 2b CLOVER WaM: 83.6% ORR, 61.8% MRR, median DoR 17.8 months in r/r WM.","BTKi-exposed: 64.1% MRR, median PFS 15.9 mo; BTKi-refractory: 63.6% MRR, median PFS 14.8 mo.","Nantahala gets board seat; warrants exercisable upon stockholder approval at $2.65.","Proceeds to support Phase 3 trial of iopofosine I 131 for Waldenström macroglobulinemia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102286,"accession_number":"0001104659-26-023169","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar Biosciences reports FY2025 net loss $21.8M, cash $13.2M; plans EMA submission Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.8M ($8.35/share) vs $44.6M ($36.52/share) in 2024; company pre-revenue.","Cash $13.2M at Dec 31, 2025, expected to fund operations into Q3 2026.","Plans to submit Conditional Marketing Authorization for iopofosine I 131 to EMA in Q3 2026.","Initiated Phase 1b study of CLR 125 in triple negative breast cancer; early data mid-2026.","Received FDA Breakthrough Therapy Designation for iopofosine I 131 in relapsed/refractory WM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118577,"accession_number":"0001104659-25-110848","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar Q3 net loss $4.4M ($1.41/sh); cash $12.6M; progress on EU conditional marketing for iopofosine","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $4.4M ($1.41/sh) from $14.7M ($11.18/sh) YoY; R&D spending fell to $2.5M.","Cash $12.6M at Sep 30, plus $5.8M from Oct warrant exercises; runway into Q3 2026.","EMA SAWP confirmed iopofosine I 131 may qualify for Conditional Marketing Approval in WM; submission planned 2026.","Phase 1b of CLR 125 (Auger-emitter) for triple-negative breast cancer initiated; RPDD granted for iopofosine in pediatric high-grade glioma.","Raised ~$12.7M in Q3; funds to advance TNBC study and EMA application."],"consensus_eps_estimate":-2.578,"consensus_eps_actual":-7.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118576,"accession_number":"0001104659-25-098725","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["1.01","2.02","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Cellectar raises ~$5.8M via warrant exercise; prelim cash $12.6M as of Sep 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$5.8M from exercise of 1,048,094 existing warrants at $5.25/share; holders paid $0.125 per new warrant.","Preliminary cash and equivalents ~$12.6M as of Sep 30, 2025; combined with net proceeds of ~$5.2M, runway extends into Q3 2026.","Issued Series I warrants (exercisable at $6.00, 5-yr term) and Series II warrants (exercisable at $6.00, 18-mo term) for 100% of exercised shares.","Company to file a resale registration statement for new warrant shares within 15 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118575,"accession_number":"0001104659-25-096928","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"EMA confirms iopofosine I 131 eligible for Conditional Marketing Authorization in post-BTKi WM","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SAWP advised filing a CMA for iopofosine I 131 in post-BTKi refractory WM could be acceptable.","CMA submission planned for early 2026; potential commercial launch in up to 30 EMA countries by 2027.","CLOVER WaM Phase 2 study showed ORR 83.6%, MRR 58.2%; >70% patients were post-BTKi.","Company also pursuing US NDA under accelerated approval, contingent on funding for confirmatory study.","Estimated 35,000-45,000 WM patients in Europe with significant unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135049,"accession_number":"0001104659-25-078102","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar to pursue accelerated NDA for iopofosine I 131 in WM; Q2 net loss $5.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Plans NDA submission for accelerated approval of iopofosine I 131 in WM, subject to sufficient funding and confirmatory trial initiation.","FDA granted Breakthrough Therapy Designation for iopofosine I 131; EMA decision on conditional approval expected late Q3/early Q4 2025.","Raised ~$9.5M in June/July financings; cash $11.0M at June 30, 2025, plus July net proceeds funds operations into Q2 2026.","CLR 125 Phase 1 TNBC trial protocol submitted to FDA; plan to advance into clinic 4Q 2025/early 2026.","Q2 2025 net loss $5.4M ($3.39 per share); R&D $2.4M, G&A $3.6M; both down YoY."],"consensus_eps_estimate":-3.978,"consensus_eps_actual":-7.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152013,"accession_number":"0001104659-25-062837","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cellectar provides clinical updates, plans Phase 1 studies for CLR 125 and CLR 225 in H2 2025 subject to financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CLR 125 (Auger-emitting PRC) Phase 1b study in triple-negative breast cancer planned for H2 2025, subject to additional financing.","CLR 225 (alpha-emitting, actinium-225) Phase 1 imaging and dose-escalation safety study in solid tumors planned for H2 2025, subject to financing.","CLOVER-WaM study of iopofosine I 131 in Waldenström macroglobulinemia met primary endpoint with MRR of 58.2% (p<0.0001), ORR 83.6%, and 7.3% CR rate.","No treatment-related deaths in CLOVER-WaM study; most common Grade 3+ TRAEs were thrombocytopenia (81.5%) and neutropenia (66.2%), all patients recovered.","Proposed securities offering to fund operating expenses and initiate CLR 125 and CLR 225 clinical studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152012,"accession_number":"0001104659-25-062639","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Cellectar Biosciences completes 1-for-30 reverse stock split effective June 24, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse split ratio set at 1-for-30 for common stock, par value $0.00001.","Amendment to Second Amended and Restated Certificate of Incorporation filed.","Fractional shares not issued; aggregate fractions sold by transfer agent and net proceeds distributed pro rata."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152011,"accession_number":"0001104659-25-060661","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cellectar Biosciences announces 1-for-30 reverse stock split; effective June 24, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved by stockholders at June 13, 2025 annual meeting; board set final ratio as 1-for-30.","Reduces outstanding shares from ~54.4M to ~1.8M; effective at 12:01 a.m. ET on June 24.","Fractional shareholders will receive cash in lieu; authorized shares and par value unchanged.","Ticker remains CLRB on Nasdaq; new CUSIP number 15117F880 begins June 24.","Outstanding options, warrants, and preferred stock conversion ratios adjust proportionately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152010,"accession_number":"0001104659-25-059400","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cellectar shareholders approve reverse stock split, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected James V. Caruso and Frederick W. Driscoll as Class II directors; Caruso 5,478,892 for, Driscoll 6,207,218 for.","Ratified Deloitte & Touche as independent auditor for FY2025 with 16,651,803 votes for, 219,578 against.","Approved reverse stock split of common stock at ratio 1:10 to 1:30, as determined by Board; 13,464,719 for.","Approved non-binding advisory vote on named executive officer compensation: 5,050,203 for, 2,230,519 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152009,"accession_number":"0001104659-25-056697","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["1.01","3.02","3.03","7.01","9.01"],"status":"ready","headline":"Cellectar Biosciences raises $2.5M via warrant exercise inducement at $0.3041/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2.5M from immediate exercise of 8,301,322 outstanding warrants at $0.3041/share.","Warrants originally issued on June 5, 2020, Oct 25, 2022, and July 21, 2024; no replacement warrants issued.","Closing expected on or about June 6, 2025; Ladenburg Thalmann acting as exclusive placement agent.","Net proceeds for general corporate purposes including working capital and operating expenses.","All shares underlying the warrants are registered or resale-registered with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152008,"accession_number":"0001104659-25-047568","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar Biosciences Q1 2025 Net Loss Narrowed to $6.6M; Seeks EMA Conditional Approval for Iopofosine","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q1 2025 was $6.6 million ($0.14 per share), compared to $26.6 million ($0.91 per share) in Q1 2024.","Company seeking conditional EMA approval for iopofosine I 131 in Waldenstrom macroglobulinemia based on CLOVER WaM Phase 2 data with 59% major response rate in BTKi-treated patients.","Cash and cash equivalents totaled $13.9 million as of March 31, 2025, expected to fund operations into Q4 2025.","Board engaged Oppenheimer & Co. as exclusive financial advisor to explore strategic alternatives including mergers, acquisitions, or partnerships.","Planned Phase 3 study for iopofosine I 131 would be a comparator randomized controlled study with 100 patients per arm, dependent on funding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152007,"accession_number":"0001104659-25-042870","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cellectar Biosciences to explore strategic alternatives; hires Oppenheimer as advisor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized exploration of M&A, partnerships, licensing or other transactions; no deal reached.","Oppenheimer & Co. retained as exclusive financial advisor for the strategic evaluation process.","CEO James Caruso cites need for a partner to develop lead asset iopofosine I-131 and pipeline.","Alpha- and Auger-emitting radioconjugates CLR 225 and CLR 125 in solid tumors are additional opportunities.","No timetable set; company will not update progress unless a definitive agreement is reached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170846,"accession_number":"0001104659-25-024446","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Cellectar amends CEO/COO severance, reduces stockholder quorum to one-third","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board on March 12, 2025 approved enhanced severance for CEO and COO upon qualifying termination after a change in control.","CEO James V. Caruso gets 24 months base salary, target bonus, and benefit continuation.","COO Jarrod Longcor gets 18 months base salary and benefit continuation.","On March 11, 2025, Board adopted amended Bylaws reducing stockholder quorum from a majority to one-third of shares.","Bylaws also revise procedural requirements for stockholder nominations and other business, and align with Delaware law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170845,"accession_number":"0001104659-25-023216","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar Biosciences FY2024 net loss $44.6M; FDA agrees on accelerated approval path for iopofosine I 131","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $44.6M ($1.22 basic EPS) vs $42.8M in 2023; cash $23.3M as of Dec 31, 2024.","FDA aligned on regulatory path for accelerated approval of iopofosine I 131 in WM; confirmatory study (100/arm) expected to cost $40M-$45M.","Phase 2 CLOVER-WaM data: ORR 83.6%, MRR 58.2% (exceeded FDA 20% endpoint).","G&A expenses surged to $25.6M from $11.7M due to commercialization infrastructure; R&D $26.1M slightly down.","IND cleared for Auger-emitting radioconjugate; alpha-emitting IND planned H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170844,"accession_number":"0001104659-25-008127","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cellectar receives Nasdaq minimum bid price deficiency notice; 180-day cure period until July 29, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice from Nasdaq on Jan 30, 2025 for failure to maintain $1.00 minimum bid price per Nasdaq Listing Rule 5550(a)(2).","No immediate impact on listing; common stock remains on Nasdaq Capital Market.","Company has 180 calendar days, until July 29, 2025, to regain compliance.","If not cured, Company may be eligible for an additional 180-day extension subject to meeting other listing standards.","Failure to regain compliance could lead to delisting; Company may request a hearing to stay any delisting action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170843,"accession_number":"0001104659-25-003208","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cellectar reports iopofosine 83.6% ORR in WM; plans confirmatory study for accelerated approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Iopofosine I 131 achieved 83.6% ORR and 58.2% MRR in Phase 2 CLOVER-WaM for Waldenstrom's Macroglobulinemia; primary endpoint of 20% MRR exceeded.","Company expects confirmatory randomized study (40-60 patients/arm) with FDA alignment in H1 2025; cash runway through Q4 2025.","Advancing alpha-emitting PRC CLR 121225 into Phase 1/2a solid tumor studies; IND filing expected Q1 2025.","Auger-emitting PRC CLR 121125 IND cleared; Phase 1b/2a dose finding study in triple-negative breast cancer planned.","Company pursuing partnerships for iopofosine; presentation at Biotech Showcase on Jan 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187807,"accession_number":"0001104659-24-127487","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["2.05","8.01","7.01","9.01"],"status":"ready","headline":"Cellectar pivots away from iopofosine I 131 accelerated approval; cuts workforce 60%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Due to FDA Type-C meeting, accelerated approval for iopofosine I 131 would now require randomized confirmatory study with PFS endpoint; company seeking strategic options for this program.","Workforce cut ~60%; expects annual operating cost savings of ~$7.5M and ~$1.7M severance costs in Q4 2024/Q1 2025.","Shifting focus to alpha- (CLR 121225) and Auger-emitter (CLR 121125) programs; expects to file IND applications in H1 2025 for Phase 1 solid tumor studies.","Restructuring expected to extend cash runway into Q3 2025 from earlier depletion estimate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187806,"accession_number":"0001104659-24-119941","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar Q3 cash $34.3M; raised $19.4M with potential $73.3M; positive WM data supports NDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $34.3M at Sept 30, 2024, up from $9.6M at Dec 31, 2023; raised $19.4M from warrant exercises with potential for additional $73.3M.","Q3 R&D expenses $5.5M (down from $7.0M YoY) due to end of WM pivotal enrollment; G&A $7.8M (up from $2.4M YoY) for commercialization prep.","Positive Phase 2 CLOVER-WaM results for iopofosine I 131 in WM; planning near-term NDA submission for accelerated approval.","Data selected for oral presentation at ASH meeting on Dec 9, 2024.","Entered supply agreements (SpectronRx, Northstar) and collaboration with City of Hope for mycosis fungoides."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187805,"accession_number":"0001104659-24-119738","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cellectar files revised auditor consent to correct omitted registration statements","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Revised auditor consent filed Nov 15, 2024 for Form 10-K/A filed Oct 29, 2024.","Original consent omitted references to 12 registration statements (Forms S-1, S-1 MEF, S-3).","No changes to previously reported financial results or other disclosures.","Revised consent covers all historical registration statements as of Nov 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187804,"accession_number":"0001104659-24-113549","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cellectar regains Nasdaq compliance after filing restated financials and Form 10-Q","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter dated Oct 31, 2024 confirming compliance with Listing Rule 5250(c)(1).","Filed on Oct 29, 2024 restated audited financials for FY2022 and FY2023 and restated quarterly periods in 2022-2023.","Also filed restated Q1 2024 quarterly report (Form 10-Q/A) and regular Q2 2024 quarterly report (Form 10-Q).","Nasdaq noted the matter is now closed, removing delisting risk from late filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204321,"accession_number":"0001104659-24-092495","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Cellectar to restate financial statements, receives Nasdaq delinquency notice for late Q2 filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Restating audited FY2022 & FY2023 and unaudited Q1-Q3 2023 & Q1 2024 due to warrant accounting error in Oct 2022 financing.","Changes are non-cash and non-operating; restatement expected to take ~6 weeks before filing Q2 2024 10-Q.","Received Nasdaq notice on Aug 20, 2024 for late Q2 10-Q; must submit compliance plan by Oct 21, 2024.","Nasdaq may grant up to 180-day extension (until Feb 17, 2025) if plan accepted; otherwise can appeal.","No immediate delisting impact, but failure to regain compliance could lead to listing suspension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204320,"accession_number":"0001104659-24-088606","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar reports Q2 2024 cash of $25.9M; pivotal WM trial shows 80% ORR, exceeding primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $25.9M as of June 30, 2024, up from $9.6M at Dec 31, 2023. Net cash used in ops Q2 2024 was $14.1M.","R&D expense $8.2M (Q2 2024) vs $6.3M (Q2 2023); G&A $6.4M vs $2.0M.","CLOVER WaM study: 80% ORR, 56.4% MRR exceeded primary endpoint of 20% MRR; median prior lines of therapy was 4.","NDA filing for iopofosine I 131 in WM planned for Q4 2024; accelerated 6-month review; potential 2025 launch.","Raised $19.4M in July 2024; cash runway into Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204319,"accession_number":"0001104659-24-087859","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Cellectar restates 2022-2024 financials; warrant accounting error triggers non-reliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board concludes FY2022, FY2023 audited and Q1-Q3 2023, Q1 2024 interim statements are unreliable.","Errors stem from accounting treatment of warrants issued in October 2022 financing.","Restatement required; company unable to estimate amount or effect at this time.","Filing of Q2 2024 Form 10-Q will be delayed pending restatement.","Discussed with current auditor Deloitte and former auditor Baker Tilly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204318,"accession_number":"0001104659-24-081680","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Cellectar's iopofosine I 131 hits primary endpoint in WM pivotal study; 56.4% MRR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CLOVER WaM study met primary endpoint: MRR 56.4% (95% CI 42-67%) vs 20% agreed target.","ORR of 80% and disease control rate 98.2% in heavily pre-treated WM patients (median 4 prior therapies).","78% of major responders progression-free at 18 months; median DoR not reached.","Company plans to submit NDA in Q4 2024 and seek priority review.","Preliminary cash and equivalents ~$25.9M as of June 30, 2024 (unaudited, subject to change)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204317,"accession_number":"0001104659-24-081307","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["1.01","3.02","3.03","7.01","9.01"],"status":"ready","headline":"Cellectar raises $19.4M via warrant exercise; new warrants could add $73.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$19.4M from exercise of Tranche B warrants at reduced price of $2.52/share.","New Tranche A, B, C warrants could generate up to $73.3M additional gross proceeds if exercised.","Tranche A warrants ($2.52 exercise) trigger on FDA assigning PDUFA date for iopofosine I 131.","Tranche B ($4.00) triggers on FDA approval; Tranche C ($5.50) on quarterly revenue >$10M from iopofosine.","Company expects to file NDA for iopofosine I 131 in Q4 2024, seeking priority review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204316,"accession_number":"0001104659-24-079262","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Cellectar Biosciences dismisses Baker Tilly, hires Deloitte; cites material weaknesses","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Audit Committee dismissed Baker Tilly and is engaging Deloitte & Touche as independent auditor for FY2024, subject to standard procedures.","Baker Tilly's prior reports contained a going-concern emphasis paragraph; no disagreements except disclosed material weaknesses.","Material weaknesses identified: fair value methodologies for Level 3 instruments, stock-based compensation controls, and segregation of duties/user access.","No prior consultations with Deloitte on accounting principles or disagreements during fiscal years 2022-2023 and interim 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221088,"accession_number":"0001104659-24-074747","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Cellectar Biosciences amends NJ lease, adds 7,829 sq ft, aggregate rent ~$2.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment of Lease with Campus 100 LLC; total leased area becomes 11,812 sq ft.","Expiration extended from April 2029 to the last day of the 74th lease month after commencement.","Additional security deposit of $45,669.17; total security deposit now $69,235.25.","Aggregate rent under amended lease approximately $2,534,000 plus share of operating expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221087,"accession_number":"0001104659-24-071822","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cellectar stockholders approve increase in share reserve by 7M shares, re-elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to 2021 Stock Incentive Plan, increasing shares reserved by 7,000,000 (14.5M for, 1.06M against).","Class I directors Asher Chanan-Khan and John Neis re-elected with 15.4M and 14.9M votes for, respectively.","Ratification of Baker Tilly US, LLP as independent auditor for FY2024 approved (25.8M for, 183k against).","Non-binding advisory vote on executive compensation approved (15.1M for, 436k against).","No departures or other material changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221086,"accession_number":"0001104659-24-060865","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar Q1 net loss $0.74/share; cash $40M; WM study data in June","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.6M ($0.74/share) in Q1 2024 vs $8.6M ($0.76/share) in Q1 2023; cash $40.0M.","CLOVER WaM pivotal study met primary endpoint: major response rate 61%; full data in June; NDA submission on track for H2 2024.","Cash $40.0M as of March 31, 2024, expected to fund operations into Q4 2024; net cash used in operations ~$13M in Q1.","Phase 1b pediatric high-grade glioma study enrolled first patient; data expected H2 2024.","Preclinical data for alpha-emitting CLR 121225 in pancreatic cancer; phase 1 planned by Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240666,"accession_number":"0001104659-24-039341","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar reports FY2023 net loss $38M; plans iopofosine NDA submission H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.0M ($3.11 per share) vs $28.6M ($4.05) in prior year.","Cash $9.6M at Dec 31, 2023; plus $44.1M from Jan 2024 warrant exercise funds into Q4 2024.","CLOVER WaM study met primary endpoint: MRR 61%, ORR 75.6%, 7.3% CR in refractory WM.","R&D expense $28.2M, up 47% YoY, driven by manufacturing for trials and commercial readiness.","Positive topline data announced; NDA submission planned H2 2024 with request for accelerated approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240665,"accession_number":"0001104659-24-009664","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cellectar reports share count update after warrant exercises; 30.45M common shares outstanding as of Jan 31, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common shares outstanding: 30,452,042 as of January 31, 2024, up from prior count due to Tranche A and other warrant exercises since November 2023.","Preferred stock outstanding: 319.76 Series E-2, 918.00 Series E-3, and 111 Series D preferred shares.","Warrant exercises increased share count, diluting existing common stockholders.","No business updates or financial results provided; filing solely updates capital structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240664,"accession_number":"0001104659-24-006709","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cellectar reports full exercise of Tranche A warrants raising $44.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tranche A warrants from September 2023 financing exercised in full.","Gross proceeds of approximately $44.1 million from the warrant exercise.","No other details on use of proceeds provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240663,"accession_number":"0001104659-24-002401","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cellectar announces positive pivotal trial data for iopofosine I 131 in WM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CLOVER-WaM study met primary endpoint with 61% major response rate (p<0.0001), exceeding 20% statistical hurdle.","Overall response rate of 75.6% and 100% disease control in heavily pretreated, BTKi-refractory WM patients.","Median duration of response not yet reached at median 8-month follow-up; 76% remain progression-free.","No treatment-related discontinuations or deaths; Grade 3+ cytopenias manageable with no bleeding or febrile neutropenia beyond 2%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258160,"accession_number":"0001104659-23-122057","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cellectar regains Nasdaq compliance via $35M+ market value of listed securities","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Cellectar on Nov 21, 2023, that it meets the $35M minimum market value of listed securities under Rule 5550(b)(2), resolving the deficiency.","Prior deficiency: stockholders' equity was $(467,000) as of June 30, 2023, below the $2.5M minimum required under Rule 5550(b)(1).","The company had been at risk of delisting since August 16, 2023; compliance is now fully restored."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258159,"accession_number":"0001104659-23-113593","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar to release top-line WM pivotal data at JP Morgan Conference week of Jan 8, 2024; raises up to $102.9M via PIPE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Top-line data from Waldenstrom's macroglobulinemia pivotal trial to be released week of Jan 8, 2024 at JP Morgan Healthcare Conference.","Closed PIPE with up to $102.9M gross proceeds (milestone-based); initial $24.5M at $1.82/share; led by Rosalind Advisors.","Received EMA PRIME designation for iopofosine I 131 in WM after two or more prior treatments.","Cash of $19.0M at Sep 30; net $22.2M from PIPE; believes funded into Q2 2024.","Q3 R&D expense $7.3M (up from $5.4M YoY); G&A $2.1M (down from $2.4M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258158,"accession_number":"0001104659-23-112202","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["5.03","5.07","8.01","9.01"],"status":"ready","headline":"Cellectar shareholders approve 10M share increase; Nasdaq OKs compliance plan with Feb 12 deadline","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common stock from 160M to 170M shares at special meeting on Oct 25.","Issuance proposal (conversion of Series E Preferred >19.99% of outstanding) approved with 3,318,009 votes for, 236,357 against.","Nasdaq non-compliance with $2.5M stockholders' equity rule; plan approved; deadlines: Jan 4 warrant update, Feb 12 compliance evidence.","Failure to demonstrate compliance by Q1 2024 filing may result in delisting; company cautions no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275470,"accession_number":"0001104659-23-099368","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Cellectar raises $24.5M via private placement of Series E-1 preferred stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $24.5M selling 1,225 shares Series E-1 Preferred Stock at $20,000/share plus warrants for additional preferred shares.","Series E-1 convertible into common at $1.82/share (subject to stockholder approval); warrants have exercise prices $3.185-$4.7775/share.","Warrants exercisable upon milestones: positive CLOVER-WaM topline data (Tranche A ~$44.1M) or FDA NDA approval for iopofosine I 131 (Tranche B ~$34.3M).","Filed Certificate of Elimination for Series A/B/C preferred; reduced Series D authorized shares from 1,519 to 111.1111.","Proceeds for working capital; Oppenheimer & Co. placement agent with 7% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275469,"accession_number":"0001104659-23-093947","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cellectar Biosciences receives Nasdaq delisting notice over negative stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of ($467,004) as of June 30, 2023, below Nasdaq's $2.5M minimum.","Company has until September 30, 2023 to submit a compliance plan to Nasdaq.","If plan accepted, extension possible until February 12, 2024; delisting risk remains.","No immediate impact on listing; hearing process available if delisting determined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275468,"accession_number":"0001104659-23-091006","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar Q2 net loss $8.2M; cash $5.2M; WM pivotal data expected 2H23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss ($8.2M, $0.73/sh) vs ($7.4M, $1.22/sh) in Q2 2022; R&D expense $6.3M, up 40% YoY.","Cash $5.2M at June 30, 2023, down from $19.9M at Dec 31, 2022; cash runway into Q4 2023.","WM CLOVER-WaM pivotal top-line data expected 2H23; NDA and 2024 product launch on target.","Phase 1b in pediatric high-grade gliomas to start Q3 2023; CNSL cohort expanded after complete response.","Multiple myeloma data: 40-62% response rates in triple-class refractory and post-BCMA patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292980,"accession_number":"0001104659-23-076346","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cellectar presents iopofosine I 131 MM data: 32% ORR at optimal dose >60 mCi TAD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Overall response rate 23% in 64 evaluable patients; 32% ORR at optimal >60 mCi TAD dose.","Clinical benefit rate 75% and disease control rate 85.7% at >60 mCi TAD.","Triple-class refractory patients achieved 46% ORR (median PFS 3.4 mo); quad-class 50% ORR.","Grade 3/4 cytopenias common (62.5% thrombocytopenia, anemia, neutropenia); no off-target toxicities.","Drug given as four 15-min IV infusions over 3 months with low-dose dexamethasone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292979,"accession_number":"0001104659-23-075997","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cellectar stockholders approve 1.1M share increase to stock plan, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 1,100,000-share increase to 2021 Stock Incentive Plan (3,025,557 for, 389,584 against).","Class III directors Stefan D. Loren, Ph.D. and Douglas J. Swirsky re-elected to three-year terms.","Ratification of Baker Tilly US, LLP as independent auditor for FY2023 approved (5,283,070 for, 54,947 against).","Non-binding advisory vote on executive compensation approved (3,100,012 for, 311,122 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292975,"accession_number":"0001104659-23-072483","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K/A","filed_at":"2023-06-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cellectar Biosciences corrects adjourned annual meeting to virtual, reconvenes June 23","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Adjourned 2023 annual meeting reconvenes Friday, June 23, 2023 at 10:00 AM ET via virtual platform.","Correction from original filing: meeting will be held virtually, not at company headquarters.","Stockholders as of April 25, 2023 can attend, vote, and submit questions online using control number.","Proposals to be voted on unchanged from prior proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292978,"accession_number":"0001104659-23-071211","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cellectar Biosciences adjourns 2023 annual meeting due to lack of quorum; reconvenes June 23","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting adjourned on June 14, 2023; insufficient shares present for quorum.","Adjourned meeting to reconvene June 23, 2023, at 10:00 AM at Florham Park, NJ headquarters.","Record date remains April 25, 2023; proposals unchanged.","Company continues to solicit votes; stockholders urged to vote by June 22, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292977,"accession_number":"0001104659-23-070826","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cellectar delays WM pivotal trial top-line data to H2 2023; pediatric glioma trial to start Q3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Top-line data from WM CLOVER-WaM trial delayed to H2 2023; 2024 product launch still targeted.","All 49 sites now active; enrollment accelerated after initial delays from site contracting and regulatory responses.","Plans to initiate Phase 1b study in pediatric high-grade gliomas in Q3 2023, supported by $2M NCI grant.","Iopofosine I 131 showed 100% ORR, 83.3% major response rate in Phase 2a WM study (6 patients).","Fast Track Designation allows 6-month FDA review; platform expands to alpha-emitter, siRNA, and peptide payloads."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292976,"accession_number":"0001104659-23-055815","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar reports Q1 net loss of $8.6M; cash at $12.7M with runway into Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of ($8.6M) or ($0.76)/share vs ($6.1M) or ($1.00)/share in Q1 2022.","Cash and equivalents $12.7M at March 31, 2023, down from $19.9M at Dec 31, 2022.","R&D expense rose to $6.7M from $3.9M YoY on clinical, manufacturing costs.","G&A expense decreased to $2.1M from $2.3M YoY driven by lower professional fees.","Enrolling pivotal iopofosine trial in Waldenstrom's; topline data expected in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313633,"accession_number":"0001104659-23-030354","cik":1279704,"company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cellectar FY2022 net loss $28.6M ($4.05/share); cash $19.9M, runs to Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $28.6M ($4.05/share) vs $24.1M ($4.35/share) in 2021.","Cash $19.9M at 12/31/22 vs $35.7M at 12/31/21; operating cash used $25.2M; funds into Q4 2023.","R&D $19.2M (up $1.6M); G&A $9.5M (up $3.0M) from prior year.","Lawsuit resolved with WARF; non-exclusive license secured; all claims against Drs. Weichert and Pinchuk dismissed.","Appointed Shane Lea as CCO and Dr. Andrei Shustov as SVP Medical; positive clinical data including CNS lymphoma complete response."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25813554.117834393,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-09T23:59:59+00:00|313633"}